Utility of APOE testing for reducing ARIA under probabilistic stopping rates to treat with anti-amyloid therapy for ε4-homozygote patients: A simulation study

Background: APOE ε4/ε4 genotype increases the risk of Amyloid-Related Imaging Abnormalities (ARIA) from anti-amyloid antibody treatment (AAT). While guidelines recommend testing, its practical utility depends on the resulting probability (p) that treatment is actually withheld for ε4-homozygotes, wh...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kenichiro Sato, Yoshiki Niimi, Masanori Kurihara, Ryoko Ihara, Atsushi Iwata, Takeshi Iwatsubo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-01-01
coleção:	JAR Life
Assuntos:	APOE Anti-amyloid treatment ARIA Number needed to test Alzheimer's Disease Shared decision-making
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2534773X26000017
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!